PEPTIDOGLYCAN ANALYSIS OF VSE AND VRE

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 粪肠球菌是一种机会致病菌，在人类感染中占相当大的比例，尤其是在医院。由于肠球菌对许多种类的抗生素(如青霉素)表现出内在的耐药性，最成功的治疗方法是糖肽。糖肽通过扰乱细胞壁的完整性导致细菌细胞死亡。最强的糖肽，也就是所谓的“最后的药物”，就是万古霉素。然而，自1988年以来，对万古霉素耐药的感染发生率迅速上升。解决肠球菌耐药性的问题需要了解细胞壁肽聚糖的生物合成和组织，它是万古霉素的潜在结合部位。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Enterococcus faecium, an opportunistic pathogen, causes a substantial proportion of enterococcal human infections, particularly in hospitals. Due to the intrinsic resistance that enterococci demonstrate towards many categories of antibiotics (e.g., penicillins), the most successful treatment has been glycopeptides. Glycopeptides cause bacterial cell death by perturbing the integrity of the cell wall. The most powerful glycopeptide, the so-called "drug of last resort," is vancomycin. However, the incidence of infections resistant to vancomycin has increased rapidly since 1988. Solving the problem of enterococcal resistance requires an understanding of the biosynthesis and organization of the cell-wall peptidoglycan, a potential binding site of vancomycin.